ASTRIDE, NCT05468489: To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC |
|
|
| Recruiting | 3 | 200 | US | Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide) | Shanghai Henlius Biotech | Extensive Stage Small Cell Lung Cancer | 04/25 | 12/25 | | |
| Terminated | 2 | 205 | Europe, US, RoW | ladiratuzumab vedotin, SGN-LIV1A, pembrolizumab, Keytruda | Seagen Inc., Merck Sharp & Dohme LLC | Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma | 11/23 | 11/23 | | |
